Table 3 Antibiotic treatment and 28-day mortality per risk category of the abbMEDS and CURB-65
n (%) | Low risk | Intermediate risk | High risk | |||
|---|---|---|---|---|---|---|
Patients | Mortality | Patients | Mortality | Patients | Mortality | |
AbbMEDS | ||||||
No antibiotics | 52 (15.7) | 1 (1.9) | 20 (6.6) | 4 (20.0) | 0 | 0 |
Oral | 41 (12.4) | 0 | 21 (7.0) | 3 (14.3) | 0 | 0 |
IV narrow-spectrum | 22 (6.6) | 0 | 10 (3.3) | 1 (10.0) | 0 | 0 |
IV broad-spectrum | 216 (65.3) | 11 (5.1) | 251 (83.1) | 51 (20.3) | 39 (100.0) | 18 (46.2) |
Total (672)# | 331 (49.3) | 12 (3.6) | 302 (44.9) | 59 (19.5) | 39 (5.8) | 18 (46.2) |
CURB-65 | ||||||
No antibiotics | 54 (15.7) | 3 (5.6) | 10 (5.6) | 0 | 7 (4.4) | 1 (14.3) |
Oral | 47 (13.7) | 3 (6.4) | 13 (7.3) | 1 (7.7) | 4 (2.5) | 0 |
IV narrow-spectrum | 24 (7.0) | 0 | 5 (2.8) | 0 | 4 (2.5) | 0 |
IV broad-spectrum | 219 (63.7) | 14 (6.4) | 150 (84.3) | 23 (15.3) | 144 (90.6) | 41 (28.5) |
Total (681)# | 344 (50.5) | 20 (5.8) | 178 (26.1) | 24 (13.5) | 159 (23.3) | 42 (26.4) |